DexCom
DXCM
AIRPORTS OF THAILAND PUBLIC CO UNSP ADR EACH REP 10 ORD SHS
AIPUY
New Fortress Energy
NFE
4
LIFE HEALTHCARE GROUP HOLDINGS UNSPON ADR EA REPR 4 ORD ZAR0.00
LTGHY
5
Enerpac Tool
EPAC
US Stock MarketDetailed Quotes
CKPT Checkpoint Therapeutics
- 4.120
- 0.0000.00%
Close May 2 16:00 ET
- 4.120
- 0.0000.00%
Post 16:05 ET
358.52MMarket Cap-2.90P/E (TTM)
4.140High4.100Low1.26MVolume4.100Open4.120Pre Close5.20MTurnover2.00%Turnover RatioLossP/E (Static)87.02MShares4.50052wk High-27.28P/B259.15MFloat Cap1.47052wk Low--Dividend TTM62.90MShs Float105.000Historical High--Div YieldTTM0.97%Amplitude1.300Historical Low4.124Avg Price1Lot Size
About Checkpoint Therapeutics Company
Checkpoint Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. Its product portfolio includes CK-301, CK-101, CK-103, CK-302, and Anti-CAIX. The company was founded on November 10, 2014 and is headquartered in Waltham, MA.
Company Profile
SymbolCKPT
Company NameCheckpoint Therapeutics
Listing DateJun 26, 2017
Founded2014
CEOMr. James F. Oliviero, III
MarketNASDAQ
Employees24
Fiscal Year Ends12-31
Address95 Sawyer Road,Suite 110
CityWaltham
ProvinceMassachusetts
CountryUnited States of America
Zip Code02453
Phone1-781-652-4500
Websitehttp://www.checkpointtx.com
Company Executives
- Name
- Position
- Salary
- James F. Oliviero, III
- Director, President and Chief Executive Officer
- 9.78M
- Garrett Gray
- Chief Financial Officer, Corporate Secretary and Treasurer
- 2.76M
- Michael S. Weiss
- Chairman of the Board
- 216.44K
- Dr. Lindsay A. Rosenwald, M.D.
- Director
- 206.44K
- Neil Herskowitz
- Independent Director
- 227.69K
- Christian Bechon
- Independent Director
- 251.74K
- Barry Salzman
- Independent Director
- 287.69K
- Dr. Amit Sharma, F.A.C.P.
- Independent Director
- 230.28K
Market Insights
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma
Moo Live
Mar 20 02:25
FOMC Press Conference, March 19, 2025